Eli Lilly (LLY) Acquires Kelonia for $7 billion, Securing KLN-1010 and Entering the In Vivo CAR‑T Market
Mega Deal by Big Pharma to Advance In Vivo CAR‑T Innovation
Eli Lilly (LLY) has agreed to acquire U.S.‑based Kelonia Therapeutics for a total of $7 billion (including an upfront payment of $3.25 billion and $3.75 billion in milestones), joining the race for dominance in the in vivo CAR‑T therapy market. The transaction reflects a strategic shift by global pharmaceutical companies to overcome the physical limitations and high‑cost challenges of traditional ex vivo manufacturing. Kelonia’s iGPS (integrated Gene‑Delivery Platform System) technology and its multiple‑myeloma pipeline candidate KLN‑1010 (target: BCMA) are considered core assets. Early Phase 1 data showing a 100 % minimal residual disease (MRD)‑negative rate validated the technology and served as the decisive catalyst for the large‑scale deal.
Overcoming Ex Vivo Manufacturing and the Evolution of In Vivo Gene‑Delivery
First‑generation CAR‑T products required extraction of a patient’s T cells, ex vivo engineering, and reinfusion—a complex process that drove per‑treatment costs up to $1 million and extended manufacturing timelines to several weeks, limiting patient access. In contrast, in vivo CAR‑T approaches generate CAR‑T cells directly inside the patient using lentiviral vectors or lipid‑nanoparticle (LNP) delivery systems. This eliminates the need for lymphodepletion chemotherapy and leukapheresis, substantially reducing the physical burden on patients and lowering commercialization costs, representing a potentially transformative innovation.
Big Pharma’s Territorial Expansion and Acceleration of Deal‑by‑Deal Technology Acquisitions
Over the past one to two years, major players such as AstraZeneca (AZN), Gilead Sciences (GILD), AbbVie (ABBV), and Bristol‑Myers Squibb (BMY) have deployed substantial capital to secure leadership in this space. AstraZeneca acquired EsoBiotec for $1 billion (upfront $425 million) to obtain its platform; AbbVie purchased Capstan Therapeutics for $2.1 billion, gaining access to CD19‑targeted CPTX2309 in Phase 1; BMS bought Orbital Therapeutics for $1.5 billion and is preparing clinical studies for the CD19 candidate OTX‑201. These focused investments, coupled with the maturation of platform technologies, signal a full‑scale paradigm shift in cell and gene therapy.
Expansion into Autoimmune Indications and New Market Opportunities
In vivo CAR‑T therapies are also showing disruptive potential beyond oncology, particularly in autoimmune disease treatment. For example, Umoja Biopharma is advancing UB‑VV400, a CD22‑targeted candidate, into Phase 1 trials for non‑Hodgkin lymphoma and autoimmune indications, and has entered a co‑development partnership with AbbVie for UB‑VV111. Given that the global autoimmune‑disease market is projected to reach $156 billion–$170 billion by 2025‑2026, the ability of in vivo CAR‑T to enable repeat dosing and titration positions it as a powerful alternative to existing antibody therapies.
From an investor perspective, the in vivo CAR‑T platform dismantles the manufacturing bottlenecks and high‑cost constraints of ex vivo CAR‑T, providing a core engine to reshape the multiple‑myeloma market (≈$26 billion) and the autoimmune‑disease market (≈$156 billion). In the short term, the safety and MRD data emerging from Phase 1 candidates such as Lilly’s KLN‑1010 and AbbVie’s CPTX2309 will be the primary valuation catalysts. Over the medium to long term, researchers and industry stakeholders will aim to refine lentiviral and LNP delivery to maximize cellular targeting while mitigating graft‑versus‑host disease (GvHD), positioning in vivo CAR‑T as a first‑line therapy. As top‑tier companies—including AbbVie, BMS, and Gilead—complete multi‑billion‑dollar acquisitions, the momentum for M&A activity targeting platform owners such as Umoja Biopharma, which hold strong patent portfolios, is expected to intensify.
Source: Labiotech (rss)
https://www.labiotech.eu/trends-news/in-vivo-car-t-cell-therapy-momentum/